Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine + Pembrolizumab in Metastatic Melanoma
NCT02816021Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2017
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in melanoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 12 weeks. Started Feb 2017; status: completed.
02
Drugs
azacitidine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02816021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02816021.